뇌졸중 치료제 파이프라인 분석(2026년)(2분기 인사이트와 임상시험)

Pharmaceutical and biotechnology companies are actively advancing novel thrombolytics, neuroprotective agents, anti-inflammatory therapies, regenerative medicines, and combination approaches to address the significant unmet clinical needs in acute stroke management and long-term recovery.

Stroke remains one of the leading causes of death and long-term disability worldwide, with ischemic stroke representing the primary focus of pipeline development. Although thrombolysis and mechanical thrombectomy have significantly improved clinical outcomes, many patients remain ineligible for current interventions or continue to experience permanent neurological impairment. Drug pipeline analysis provides comprehensive insights into investigational therapies, clinical development stages, mechanisms of action, sponsor activities, regulatory trends, competitive positioning, and commercialization opportunities that are shaping the future stroke treatment landscape.

Market Drivers

Growing Global Stroke Burden

The increasing incidence of stroke resulting from aging populations, hypertension, diabetes, obesity, atrial fibrillation, and other cardiovascular risk factors continues to accelerate demand for innovative therapeutic options. The substantial healthcare and economic burden associated with stroke is encouraging sustained investment in drug discovery and clinical development.

Expansion of Next-Generation Reperfusion Therapies

Growing clinical interest in improving reperfusion outcomes has accelerated development of next-generation thrombolytic agents that offer simplified administration, faster treatment, and broader patient eligibility. Recent regulatory advances have further strengthened investment in this therapeutic area.

Increasing Focus on Neuroprotection

Pharmaceutical companies are expanding research into neuroprotective therapies designed to preserve neuronal tissue during ischemic injury and improve long-term functional recovery. These therapies represent one of the most promising areas of pipeline innovation.

Advances in Imaging-Guided Treatment

Improved neuroimaging technologies are enabling more precise patient selection and extending treatment windows, encouraging sponsors to develop therapies that complement imaging-guided stroke management strategies.

Market Restraints

High Clinical Failure Rates

Neuroprotective drug development has historically experienced high attrition rates because of complex stroke biology, heterogeneous patient populations, and difficulties in demonstrating consistent clinical benefit.

Complex Clinical Development

Stroke drug development requires rapid patient enrollment, standardized imaging protocols, large multicenter studies, and long-term neurological outcome assessment, making clinical trials expensive and operationally demanding.

Regulatory Challenges

Regulatory agencies require robust evidence demonstrating meaningful improvements in functional recovery while maintaining acceptable safety profiles, particularly regarding bleeding risk associated with reperfusion therapies.

Pipeline and Technology Insights

The global stroke drug pipeline can be segmented by development phase, stroke type, drug type, treatment type, mechanism of action, and geography.

By development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed/under regulatory review candidates. Phase II and Phase III programs represent the largest share of active development as sponsors advance promising therapies toward commercialization.

By stroke type, pipeline activity covers ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke dominates development because it represents the majority of stroke cases and offers the greatest opportunity for therapeutic innovation.

By drug type, the pipeline includes thrombolytics, antiplatelets, anticoagulants, neuroprotective agents, anti-inflammatory therapies, regenerative therapies, and other investigational drug classes. Thrombolytics remain the most active development category, while neuroprotective and regenerative therapies continue to expand as sponsors pursue complementary treatment approaches.

By treatment type, pipeline assets include intravenous medications, endovascular therapies, and surgical procedures, including mechanical thrombectomy and carotid endarterectomy. Drug developers increasingly seek therapies that complement existing interventional procedures and improve functional outcomes.

Technological innovation continues to support pipeline advancement through artificial intelligence-assisted imaging, biomarker-guided patient selection, precision medicine, adaptive clinical trial designs, and digital health platforms that improve trial efficiency and treatment optimization.

Pipeline Trends

The global stroke drug pipeline continues to evolve toward targeted and combination therapeutic strategies.

Key trends include:

• Expansion of next-generation thrombolytic development.
• Increasing investment in neuroprotective therapies.
• Growing development of combination therapies with thrombectomy.
• Broader use of imaging-guided patient selection.
• Expansion of regenerative medicine and neurological recovery programs.
• Increasing adoption of adaptive clinical trial designs.
• Greater focus on extending treatment eligibility windows.

Regional Insights

North America remains the leading region for stroke drug pipeline development because of advanced clinical research infrastructure, strong regulatory support, extensive academic collaboration, and substantial pharmaceutical investment. The United States continues to lead commercialization and late-stage clinical development.

Europe maintains a strong position through multinational clinical research networks, established stroke care systems, and active participation in global drug development programs. Imaging-guided treatment strategies continue to drive innovation across the region.

Asia-Pacific is expected to emerge as one of the fastest-growing regions for stroke drug development owing to increasing stroke prevalence, expanding clinical trial capabilities, improving healthcare infrastructure, and growing pharmaceutical investment across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening their participation in multinational clinical research through healthcare modernization, expanding stroke treatment capacity, and increasing collaboration with international pharmaceutical companies.

Competitive Landscape

The global stroke drug pipeline includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, and emerging biotechnology developers.

Leading organizations continue investing in next-generation thrombolytics, neuroprotective agents, regenerative medicine, anti-inflammatory therapies, precision medicine, and combination treatment strategies. Strategic licensing agreements, collaborative research partnerships, mergers and acquisitions, and regulatory acceleration programs remain central to competitive growth. Companies including Genentech, Boehringer Ingelheim, Roche, Novartis, Bayer, Johnson & Johnson, Daiichi Sankyo, and Sanofi are actively strengthening their stroke development portfolios.

Future Outlook

The future of the stroke drug pipeline will be shaped by continued advances in precision neurology, artificial intelligence, regenerative medicine, imaging-guided treatment, and personalized therapeutics. Expansion of neuroprotective strategies, improved understanding of stroke pathophysiology, and broader integration of digital health technologies are expected to accelerate development of innovative therapies.

Increasing adoption of adaptive trial designs, biomarker-guided development, and combination treatment approaches will improve development efficiency while creating new commercial opportunities through 2035.

Conclusion

The global Stroke Drug Pipeline Analysis highlights a rapidly expanding development landscape supported by growing neurological research investment, innovation in thrombolytic therapies, advances in neuroprotection, and increasing emphasis on improving long-term functional recovery. Although challenges related to clinical complexity, regulatory requirements, and historical failure rates remain, continued advances in precision medicine, imaging technologies, and combination therapeutic strategies are expected to accelerate innovation and strengthen future commercialization opportunities.

Key Benefits of this Report

• Comprehensive analysis of the global stroke drug pipeline across all stages of development.
• Detailed evaluation of investigational therapies, mechanisms of action, and pipeline maturity.
• Competitive assessment of sponsor activities, strategic collaborations, and licensing trends.
• Insights into regulatory developments, emerging technologies, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, contract research organizations, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Pipeline benchmarking, portfolio optimization, competitive intelligence, licensing and partnership evaluation, clinical development planning, investment analysis, regulatory strategy development, commercialization planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke drug pipeline by development phase, stroke type, drug type, treatment type, and geography
• Evaluation of pipeline assets, clinical development progress, mechanisms of action, sponsor landscape, regulatory pathways, and commercialization potential
• Assessment of strategic collaborations, licensing agreements, mergers and acquisitions, competitive positioning, and emerging therapeutic innovations
• Analysis of thrombolytics, neuroprotective therapies, regenerative medicine, antiplatelets, anticoagulants, combination therapies, and future pipeline opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Stroke Drug Pipeline Snapshot
• 1.3 Key Pipeline Highlights
• 1.4 Clinical Development Trends
• 1.5 Innovation Landscape Overview
• 1.6 Competitive Intelligence Summary
• 1.7 Probability-Adjusted Opportunity Assessment
• 1.8 Key Strategic Takeaways

2. Pipeline Overview

• 2.1 Stroke Therapeutics Development Landscape
• 2.2 Pipeline Evolution and Historical Trends
• 2.3 Pipeline Asset Distribution by Development Stage
  • 2.3.1 Preclinical Assets
  • 2.3.2 Phase I Assets
  • 2.3.3 Phase II Assets
  • 2.3.4 Phase III Assets
  • 2.3.5 Filed / Under Regulatory Review Assets
• 2.4 Pipeline Asset Distribution by Stroke Type
  • 2.4.1 Ischemic Stroke
  • 2.4.2 Hemorrhagic Stroke
  • 2.4.3 Acute Stroke
  • 2.4.4 Secondary Stroke Prevention
  • 2.4.5 Post-Stroke Recovery and Neuroprotection
• 2.5 Pipeline Asset Distribution by Sponsor Type
  • 2.5.1 Large Pharmaceutical Companies
  • 2.5.2 Biotechnology Companies
  • 2.5.3 Academic and Research Institutions
• 2.6 Pipeline Maturity Assessment
• 2.7 Emerging Development Areas

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
• 3.2 Disease Burden and Epidemiology
• 3.3 Current Standard of Care
• 3.4 Treatment Gaps and Limitations
• 3.5 Unmet Clinical Needs
  • 3.5.1 Acute Intervention Challenges
  • 3.5.2 Neuroprotection Gaps
  • 3.5.3 Long-Term Recovery Limitations
  • 3.5.4 Secondary Prevention Challenges
• 3.6 Future Therapeutic Requirements
• 3.7 Market Opportunity Assessment

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Overview
• 4.2 Mechanism-Based Pipeline Clustering
  • 4.2.1 Thrombolytic Therapies
  • 4.2.2 Antithrombotic Agents
  • 4.2.3 Neuroprotective Therapies
  • 4.2.4 Anti-Inflammatory Therapies
  • 4.2.5 Regenerative and Repair Mechanisms
  • 4.2.6 Vascular Protection Strategies
  • 4.2.7 Novel Mechanistic Approaches
• 4.3 First-in-Class versus Best-in-Class Assessment
• 4.4 Established versus Emerging Mechanisms
• 4.5 Modality-Based Analysis
  • 4.5.1 Small Molecules
  • 4.5.2 Biologics
  • 4.5.3 Cell Therapies
  • 4.5.4 Gene Therapies
  • 4.5.5 RNA-Based Therapeutics
  • 4.5.6 Combination Therapies
• 4.6 Innovation Intensity Mapping
• 4.7 Mechanism-Level Competitive Benchmarking

5. Clinical Development Intelligence

• 5.1 Clinical Development Landscape
• 5.2 Clinical Trial Activity Trends
• 5.3 Trial Design Benchmarking
  • 5.3.1 Study Design Analysis
  • 5.3.2 Sample Size Assessment
  • 5.3.3 Endpoint Benchmarking
  • 5.3.4 Duration Analysis
  • 5.3.5 Patient Selection Criteria
• 5.4 Recruitment and Enrollment Intelligence
• 5.5 Clinical Success and Failure Trends
• 5.6 Historical Attrition Analysis
• 5.7 Key Development Challenges
• 5.8 Regulatory Considerations Impacting Development
• 5.9 Clinical Development Best Practices

6. Global Stroke Drug Pipeline Report Segmentation Analysis

• 6.1 By Development Phase
  • 6.1.1 Preclinical Pipeline
  • 6.1.2 Phase I
  • 6.1.3 Phase II Pipeline
  • 6.1.4 Phase III Pipeline
  • 6.1.5 Filed / Under Review Pipeline
• 6.2 By Stroke Type
  • 6.2.1 Ischemic Stroke
    • 6.2.1.1. Thrombotic
    • 6.2.1.2. Embolic
  • 6.2.2 Hemorrhagic Stroke
  • 6.2.3 Transient Ischemic Attack
  • 6.2.4 Others
• 6.3 By Drug Type
  • 6.3.1 Thrombolytics
  • 6.3.2 Antiplatelets
  • 6.3.3 Anticoagulants
  • 6.3.4 Others
• 6.4. By Treatment Type
  • 6.4.1.IV Medication
  • 6.4.2. Endovascular Therapy
  • 6.4.3. Surgical Procedures
    • 6.4.3.1. Mechanical Thrombectomy
    • 6.4.3.2. Carotid Endarterectomy (CEA)
    • 6.4.3.3. Others

7. Probability of Success and Risk Analysis

• 7.1 Risk Assessment Framework
• 7.2 Historical Development Success Rates
• 7.3 Phase Transition Probability Analysis
  • 7.3.1 Preclinical to Phase I
  • 7.3.2 Phase I to Phase II
  • 7.3.3 Phase II to Phase III
  • 7.3.4 Phase III to Approval
• 7.4 Asset-Level Probability of Success Modeling
• 7.5 Mechanism-Level Success Probability Assessment
• 7.6 Sponsor-Level Success Benchmarking
• 7.7 Attrition Risk Analysis
• 7.8 Clinical Risk Factors
• 7.9 Regulatory Risk Factors
• 7.10 Commercial Risk Factors
• 7.11 Risk-Adjusted Pipeline Valuation
• 7.12 Probability-Weighted Revenue Forecasting

8. Launch Timeline and Commercial Potential

• 8.1 Expected Approval Timeline Assessment
• 8.2 Launch Window Forecasting
• 8.3 Competitive Launch Sequencing
• 8.4 Market Entry Analysis
• 8.5 Peak Sales Potential Assessment
• 8.6 Revenue Opportunity Forecast
• 8.7 Market Penetration Expectations
• 8.8 Commercialization Risk Analysis
• 8.9 Future Market Scenario Modeling

9. Competitive Pipeline Landscape

• 9.1 Competitive Environment Overview
• 9.2 Company-Wise Pipeline Strength Assessment
• 9.3 Leading Developers Ranking
• 9.4 Emerging Challenger Analysis
• 9.5 Asset Concentration by Sponsor
• 9.6 Mechanism Ownership Analysis
• 9.7 Innovation Leadership Assessment
• 9.8 Strategic Positioning Matrix
• 9.9 Competitive Benchmarking Dashboard
• 9.10 Future Competitive Outlook

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
  • 10.1.4 Key Development Sponsors
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
  • 10.2.4 Key Development Sponsors
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
  • 10.3.4 Key Development Sponsors
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
  • 10.4.4 Key Development Sponsors
• 10.5 Middle East and Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem
  • 10.5.4 Key Development Sponsors

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Agreements
• 12.2 Co-Development Partnerships
• 12.3 Research Collaborations
• 12.4 Strategic Alliances
• 12.5 Merger and Acquisition Activity
• 12.6 Venture Capital Investments
• 12.7 Private Equity Funding
• 12.8 Public Market Financing
• 12.9 Deal Value Trends
• 12.10 Investment Hotspots
• 12.11 Future Partnership Outlook

13. Future Outlook and Strategic Insights

• 13.1 Genentech
  • 13.1.1 Pipeline Positioning
  • 13.1.2 Strategic Priorities
  • 13.1.3 Future Growth Outlook
• 13.2 Boehringer Ingelheim
  • 13.2.1 Pipeline Positioning
  • 13.2.2 Strategic Priorities
  • 13.2.3 Future Growth Outlook
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 Pipeline Positioning
  • 13.3.2 Strategic Priorities
  • 13.3.3 Future Growth Outlook
• 13.4 Novartis AG
  • 13.4.1 Pipeline Positioning
  • 13.4.2 Strategic Priorities
  • 13.4.3 Future Growth Outlook
• 13.5 Bayer AG
  • 13.5.1 Pipeline Positioning
  • 13.5.2 Strategic Priorities
  • 13.5.3 Future Growth Outlook
• 13.6 Johnson & Johnson
  • 13.6.1 Pipeline Positioning
  • 13.6.2 Strategic Priorities
  • 13.6.3 Future Growth Outlook
• 13.7 Daiichi Sankyo
  • 13.7.1 Pipeline Positioning
  • 13.7.2 Strategic Priorities
  • 13.7.3 Future Growth Outlook
• 13.8 Sanofi
  • 13.8.1 Pipeline Positioning
  • 13.8.2 Strategic Priorities
  • 13.8.3 Future Growth Outlook
• 13.9 Novo Nordisk
  • 13.9.1 Pipeline Positioning
  • 13.9.2 Strategic Priorities
  • 13.9.3 Future Growth Outlook
• 13.10 AstraZeneca PLC
  • 13.10.1 Pipeline Positioning
  • 13.10.2 Strategic Priorities
  • 13.10.3 Future Growth Outlook
• 13.11 Merck & Co., Inc.
  • 13.11.1 Pipeline Positioning
  • 13.11.2 Strategic Priorities
  • 13.11.3 Future Growth Outlook
• 13.12 GlaxoSmithKline plc
  • 13.12.1 Pipeline Positioning
  • 13.12.2 Strategic Priorities
  • 13.12.3 Future Growth Outlook
• 13.13 Eli Lilly and Company
  • 13.13.1 Pipeline Positioning
  • 13.13.2 Strategic Priorities
  • 13.13.3 Future Growth Outlook
• 13.14 AbbVie Inc.
  • 13.14.1 Pipeline Positioning
  • 13.14.2 Strategic Priorities
  • 13.14.3 Future Growth Outlook
• 13.15 Future Competitive Scenarios
• 13.16 Emerging Innovation Themes
• 13.17 Strategic Recommendations
• 13.18 Long-Term Market Outlook (2026-2035)

14. Methodology and Data Framework

• 14.1 Research Methodology
• 14.2 Data Sources and Validation Framework
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Information System (CTIS)
  • 14.2.3 Company Pipeline Disclosures
  • 14.2.4 Regulatory Filings
  • 14.2.5 Investor Presentations
• 14.3 Asset Inclusion Criteria
• 14.4 Pipeline Classification Methodology
• 14.5 Mechanism Classification Framework
• 14.6 Probability Modeling Methodology
• 14.7 Commercial Forecasting Methodology
• 14.8 Risk Adjustment Methodology
• 14.9 Competitive Intelligence Framework
• 14.10 Data Quality Assurance Process
• 14.11 Assumptions and Limitations
• 14.12 Abbreviations and Definitions
• 14.13 Appendix: Verifiable Asset Database Structure
• 14.14 Appendix: Clinical Trial Tracking Framework
• 14.15 Appendix: Sponsor Benchmarking Framework